UM  > 中華醫藥研究院
Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors
Nie, Yingjie1,2; Yang, De1; Trivett, Anna1; Han, Zhen1; Xin, Haiyun1; Chen, Xin1,3; Oppenheim, Joost J.1
2017-10-27
Source PublicationSCIENTIFIC REPORTS
ISSN2045-2322
Volume7
Abstract

Harnessing immune system to treat cancer requires simultaneous generation of tumor-specific CTLs and curtailment of tumor immunosuppressive environment. Here, we developed an immunotherapeutic regimen capable of eliminating large established mouse tumors using HMGN1, a DC-activating TLR4 agonist capable of inducing anti-tumor immunity. Intratumoral delivery of HMGN1 with low dose of Cytoxan cured mice bearing small (empty set approximate to 0.5 cm), but not large (empty set approximate to 1.0 cm) CT26 tumors. Screening for activators capable of synergizing with HMGN1 in activating DC identified R848. Intratumoral delivery of HMGN1 and R848 plus Cytoxan eradicated large established CT26 tumors. The resultant tumor-free mice were resistant to subsequent challenge with CT26, indicating the generation of CT26-specific protective immunity. This immunotherapeutic regimen caused homing of tumor-infiltrating DC to draining lymph nodes and increased infiltration of T cells into tumor tissues. Cytoxan in this regimen could be replaced by anti-CTLA4) or anti-PD-L1. Importantly, this immunotherapeutic regimen was also curative for large established mouse Renca and EG7 tumors. Thus, we have developed a curative therapeutic vaccination regimen dubbed 'TheraVac' consisting of HMGN1 and R848 plus a checkpoint inhibitor, that can, without using exogenous tumor-associated antigen(s), eliminate various large tumors and induce tumor-specific immunity.

DOI10.1038/s41598-017-14655-8
URLView the original
Indexed BySCI
Language英语
WOS Research AreaScience & Technology - Other Topics
WOS SubjectMultidisciplinary Sciences
WOS IDWOS:000413907000009
PublisherNATURE PUBLISHING GROUP
The Source to ArticleWOS
Fulltext Access
Citation statistics
Cited Times [WOS]:9   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Corresponding AuthorYang, De; Oppenheim, Joost J.
Affiliation1.Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland, USA
2.Guizhou Provincial Peoples’ Hospital, Guiyang, Guizhou Province, China
3.University of Macau, Macau, China
Recommended Citation
GB/T 7714
Nie, Yingjie,Yang, De,Trivett, Anna,et al. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors[J]. SCIENTIFIC REPORTS,2017,7.
APA Nie, Yingjie.,Yang, De.,Trivett, Anna.,Han, Zhen.,Xin, Haiyun.,...&Oppenheim, Joost J..(2017).Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.SCIENTIFIC REPORTS,7.
MLA Nie, Yingjie,et al."Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors".SCIENTIFIC REPORTS 7(2017).
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Nie, Yingjie]'s Articles
[Yang, De]'s Articles
[Trivett, Anna]'s Articles
Baidu academic
Similar articles in Baidu academic
[Nie, Yingjie]'s Articles
[Yang, De]'s Articles
[Trivett, Anna]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Nie, Yingjie]'s Articles
[Yang, De]'s Articles
[Trivett, Anna]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.